Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
about
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)Prognostic role of YB-1 expression in breast cancer: a meta-analysisImpact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation.Targeted therapy for breast cancer prevention.Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target.Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1).GOLPH3 and YB-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.The promise and challenges of targeting RSK for the treatment of cancer.Disrupting Y-Box-Binding Protein 1 Function Using OSU-03012 Prevents Endometriosis Progression in In Vitro and In Vivo Models.Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models
P2860
Q33972424-7035C3B5-2634-4021-B52A-1A44DB15F84EQ34675192-44ECB538-B618-4797-8727-984647EE539FQ35479413-458A64E2-64C5-4587-9D94-A08B258D60DFQ35558949-CB26772B-6E3F-48B8-95AE-EEAE9149ED96Q36281839-61CF8A5E-D637-4BDD-A051-AE42EB787D31Q37190825-C629CD1D-77E7-4BDD-860F-9A80068C263FQ38293424-F99BB4C3-FE24-4C25-A148-E0DBD9F18EE6Q39004481-95D27550-4BE8-4FA9-9284-50977F5CAAD1Q39335656-4BA7A16A-9003-423E-8F9C-6394031530FBQ40720588-B8B4E56D-F1D9-4ED8-8386-C142E4B3D53FQ41396285-0F652C83-5C6B-4FBE-B014-D7088E3EE4B3Q41953034-8AB41ACE-F814-4EAF-8761-6683FF7EEB4BQ42286687-0D0CC4A8-7C28-4326-9124-2DAE3FD2A452Q50787038-70BCCDD0-0994-4BF7-8003-BE08F52AB6C0Q50895098-378BBEDA-75D4-46AC-8710-A922CFA06B46Q57794717-96677C88-E49E-45A8-95C4-9FCAD7EE45E3
P2860
Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@ast
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@en
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@nl
type
label
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@ast
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@en
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@nl
prefLabel
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@ast
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@en
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@nl
P2093
P2860
P1433
P1476
Molecular decoy to the Y-box b ...... sparing normal cell viability.
@en
P2093
Arezoo Astanehe
Connie J Eaves
Jaspreet Dhillon
Jennifer H Law
Karen Lambie
Martin E Gleave
Michelle Wang
Sandra E Dunn
Steven J M Jones
P2860
P356
10.1371/JOURNAL.PONE.0012661
P407
P577
2010-09-10T00:00:00Z